Start-Up News August 2007

In women's health, Novian offers a micro-invasive alternative to lumpectomy. Mirabilis Medica hopes to introduce a non-invasive in-office procedure for the removal of uterine fibroids. Dyn-Bioshaf believes that diagnostics that pinpoint the particular cause of infertility will ultimately help improve the success rates of the In Vitro Fertilization industry.

In the past, if the women’s health market hasn’t been a "hot spot" of investing, that’s because successful exits for medtech companies operating in that space have been few and far between. But the times are changing. The 2004 acquisition of start-up Novacept Inc. by Cytyc Corp. for $325 million [See Deal] and now the proposed $6.5 billion merger of Hologic Inc. and Cytyc, two women’s health companies, which even before the merger, had gained critical mass with an acquisition strategy, have drawn attention to the opportunities in women’s health. The Cytyc/Hologic deal would also create a stronger acquirer, one that defines women’s health as broadly encompassing breast cancer, cervical cancer, menorrhagia, osteoporosis, preterm labor, contraception, and endometriosis. [See Deal](See "Cytyc Merges with Hologic," this issue.) Now, a new crop of medtech start-ups stands ready to fill unmet needs in all of these areas, and more.

The ability of imaging technologies to find ever smaller breast tumors is putting current excisional technologies to the test. Surgeons are now required to cut out tumors that they can...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.